While high COX-2 expression is clearly linked to increasing glioma grade and is associated with worse outcomes in patients with this disease [9, 10], to our knowledge, our report is the first to demonstrate that COX-2 has direct transforming activity by increasing the malignancy of glioma cells both in vitro and in vivo. Here, PTGS2 is linked to glioma.